Abstract
We describe incidence, clinical features, serological data, response to therapy and outcome of autoimmune cytopenias (ACs), including autoimmune hemolytic anemia (AIHA) and autoimmune thrombocytopenia (AIT) in a series of 281 consecutive adults with hematological malignancies that received single-unit umbilical cord blood transplantation (UCBT) at a single institution. AIHA was diagnosed in 15 patients at a median time of 181 days (range, 25–543), 12 of them had cold antibodies (IgM). The 3-year cumulative incidence (CI) of AIHA was 5.4% (CI 95% 2.7–8.1). Concomitant infections at the time of AIHA were present in 10 patients. Five out of nine patients that received corticosteroids achieved either a PR or a CR, whereas six out of eight patients that received rituximab responded. Four patients developed AIT giving a 3-year CI of 1.4% (CI 95% 0–2.8), concomitant infections were present in three of them. Multivariable analysis showed that development of chronic GVHD (relative risk (RR) 4; 95% CI 1.1–13.7; P=0.03) and diagnosis of CML (RR 4.3; 95% CI 1.5–12.7; P=0.008) were associated with an increased risk of AC. In conclusion, AIHA and AIT are relevant and clinically significant complications in UCBT recipients, especially among those that develop chronic GVHD. Response to therapy is sub-optimal, and rituximab should be considered as a therapeutic option, in this setting were most patients had cold AIHA and a serological profile similar to that seen in cold agglutinin disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Holbro A, Abinun M, Daikeler T . Management of autoimmune diseases after haematopoietic stem cell transplantation. Br J Haematol 2012; 157: 281–290.
Sanz J, Arriaga F, Montesinos P, Ortí G, Lorenzo I, Cantero S et al. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. Bone Marrow Transplant 2007; 39: 555–561.
Daikeler T, Labopin M, Ruggeri A, Crotta A, Abinun M, Hussein AA et al. New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. Blood 2013; 121: 1059–1064.
Sanz J, Boluda JCH, Martín C, González M, Ferrá C, Serrano D et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant 2012; 47: 1287–1293.
Sanz J, Sanz MA, Saavedra S, Lorenzo I, Montesinos P, Senent L et al. Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant 2010; 16: 86–94.
Montesinos P, Sanz J, Cantero S, Lorenzo I, Martín G, Saavedra S et al. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2009; 15: 730–740.
Roback JD, Grossman BJ, Harris T, Hillyer CD (eds). Technical Manual 17th edn.American Association of Blood Banks: Arlington, 2011.
Branch DR, SySiok Hian AL, Petz LD . A new elution procedure using a nonflammable organic solvent (abstract). Transfusion 1980; 20: 635.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386–2393.
Gooley T, Leisenring W, Crowley J, Storer B . Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 665–706.
Fine J, Gray R . A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.
Team RC. R: A Language and Environment for Statistical Computing, 2012.
Chen FE, Owen I, Savage D, Roberts I, Apperley J, Goldman JM et al. Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. Bone Marrow Transplant 1997; 19: 491–495.
O'Brien TA, Eastlund T, Peters C, Neglia JP, Defor T, Ramsay NK et al. Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases. Br J Haematol 2004; 127: 67–75.
Page KM, Mendizabal AM, Prasad VK, Martin PL, Parikh S, Wood S et al. Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. Biol Blood Marrow Transplant 2008; 14: 1108–1117.
Dovat S, Roberts RL, Wakim M, Stiehm ER, Feig SA . Immune thrombocytopenia after umbilical cord progenitor cell transplant: response to vincristine. Bone Marrow Transplant 1999; 24: 321–323.
Chao MM, Levine JE, Ferrara JL, Cooling L, Cooke KR, Hutchinson RJ et al. Successful treatment of refractory immune hemolysis following unrelated cord blood transplant with Campath-1H. Pediatr Blood Cancer 2008; 50: 917–919.
Jacobson CA, Turki AT, McDonough SM, Stevenson KE, Kim HT, Kaod G et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 565–574.
Cwynarski K, Goulding R, Pocock C, Dazzi F, Craddock C, Kaeda J et al. Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions. Bone Marrow Transplant 2001; 28: 581–586.
Godder K, Pati AR, Abhyankar SH, Lamb LS, Armstrong W, Henslee-Downey PJ . De novo chronic graft-versus-host disease presenting as hemolytic anemia following partially mismatched related donor bone marrow transplant. Bone Marrow Transplant 1997; 19: 813–817.
Rovira J, Cid J, Gutiérrez-García G, Pereira A, Fernández-Avilés F, Rosiñol L et al. Fatal immune hemolytic anemia following allogeneic stem cell transplantation: report of 2 cases and review of literature. Transfus Med Rev 2013; 27: 166–170.
Petz LD . Cold antibody autoimmune hemolytic anemias. Blood Rev 2008; 22: 1–15.
Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004; 103: 2925–2928.
Matzinger P . The danger model: a renewed sense of self. Science 2002; 296: 301–305.
Abrahamsen IW, Sømme S, Heldal D, Egeland T, Kvale D, Tjønnfjord GE . Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease. Haematologica 2005; 90: 86–93.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.
Acknowledgements
This work was supported in part by the Cooperative Research Thematic Network (RTICC). Grant RD12/0036/014 (ISCIII & ERDF). We thank David Pellicer and Shirley Weiss for data collection and management.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Sanz, J., Arango, M., Carpio, N. et al. Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience. Bone Marrow Transplant 49, 1084–1088 (2014). https://doi.org/10.1038/bmt.2014.107
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2014.107
This article is cited by
-
Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Bone Marrow Transplantation (2020)
-
Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation
Bone Marrow Transplantation (2019)
-
Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation
Annals of Hematology (2018)
-
ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation
Bone Marrow Transplantation (2017)
-
Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab
Bone Marrow Transplantation (2016)